On February 25, 2025, the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older."
Following this announcement and subsequent reporting by media outlets, Valneva's American Depositary Receipt ("ADR") price fell over 13% on February 28, 2025.
To receive more information, please fill out the form.
